Tumour lineage shapes BRCA-mediated phenotypes-Reference-Cited by-同舟云学术

Tumour lineage shapes BRCA-mediated phenotypes

Published:2019-07 Issue:7766 Volume:571 Page:576-579
ISSN:0028-0836
Container-title:Nature
language:en
Short-container-title:Nature

Author:

Jonsson Philip,Bandlamudi Chaitanya,Cheng Michael L.,Srinivasan Preethi,Chavan Shweta S.,Friedman Noah D.,Rosen Ezra Y.,Richards Allison L.,Bouvier Nancy,Selcuklu S. Duygu,Bielski Craig M.,Abida Wassim,Mandelker Diana,Birsoy Ozge,Zhang Liying,Zehir Ahmet,Donoghue Mark T. A.,Baselga José,Offit Kenneth,Scher Howard I.,O’Reilly Eileen M.,Stadler Zsofia K.,Schultz Nikolaus,Socci Nicholas D.,Viale Agnes,Ladanyi Marc,Robson Mark E.,Hyman David M.,Berger Michael F.,Solit David B.,Taylor Barry S.

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/s41586-019-1382-1.pdf

Reference49 articles.

1. Wooster, R. et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 378, 789–792 (1995).

2. Miki, Y. et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266, 66–71 (1994).

3. Roy, R., Chun, J. & Powell, S. N. BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nat. Rev. Cancer 12, 68–78 (2011).

4. Kuchenbaecker, K. B. et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. J. Am. Med. Assoc. 317, 2402–2416 (2017).

5. Paluch-Shimon, S. et al. Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening. Ann. Oncol. 27 (suppl 5), v103–v110 (2016).

Cited by 317 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Precision oncology: current and future platforms for treatment selection;Trends in Cancer;2024-09

2. Clinical utility of BRCA and ATM mutation status in circulating tumour DNA for treatment selection in advanced pancreatic cancer;British Journal of Cancer;2024-08-28

3. Probing the relevance of BRCA1 and BRCA2 germline pathogenic variants beyond breast and ovarian cancer;JNCI: Journal of the National Cancer Institute;2024-08-22

4. Understanding homologous recombination repair deficiency in biliary tract cancers: clinical implications and correlation with platinum sensitivity;ESMO Open;2024-08

5. Pharmacogenetics in Oncology: A useful tool for individualizing drug therapy;British Journal of Clinical Pharmacology;2024-07-30